1Cannistra S. Is there a best choice of second-line agent in the treatment of recurrent , potentially platinum-sensitive ovarian cancer [J]?J Clin Oncol, 2002, 20(5): 1158-1160
2Rose PG, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma[J].J Clin Oncol, 1998, 16(4): 1494～1497
3Dizon DS, Hensley ML, Poynor EA, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer [J]. J Clin Oncol,20
4Cantu MG, Parma BG, Rossi R, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens[J]. J Clin Oncol,20
5Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone versus carboplatin plus epidoxorubicin as second-line therapy for cisplatin or carboplatin sensitve ovarian cancer[J]. Gynecol Oncol,2001, 81(1): 3-9
6du Bios A, Luck HJ, Pifsterer J, et al. Sencond-line carboplatin and gemcitabine in platinum sensitive ovarian cancer- a dosefinding study by the AGO ovarian cancer study group [J]. Ann Oncol, 2001, 12(8):1115～1120
7Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistent and platinum-sen-sitive ovarian carcinoma: a GOG study[J].J Glin Oncol, 1998, 16(2): 405-410
8Meyer T, Nelstrop AE, Mahmoudi M, et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer[J]. Ann Oncol, 2001, 12(12):1705-1709
9Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase Ⅱ study of the European organization for research and treatment of Cancer Gynecology Group[J]. J Glin Oncol
10Ten Blokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer[J].J Clin Oncol, 1997, 15(6):2183-2193
10Piccart M T, Gore M, Huinink W T B, et al. Docetaxel,an active new drug for treatment of advanced epithelial ovarian cancer[J]. J Clin Oncol, 1995, 87(9):676-681.
